AGL heads into the post-earnings session having tripled from the canvas — and the Street's response is already turning cooler.
The stock closed Tuesday at $26.74, up 149% over the past month. That recovery traces almost directly to a mass short-covering event. Estimated short interest plunged roughly 96% across April, from around 27 million shares at the end of March to fewer than 960,000 now — less than 0.25% of the free float. What had been one of the more crowded short positions in health care services effectively ceased to exist in a matter of weeks, fuelling the violent price squeeze that carried the stock from the low teens into the mid-twenties.
The lending market reflects just how complete that unwind has been. Availability has loosened dramatically, and cost to borrow has fallen back to 0.82% — well below the brief spike above 2.5% seen in late April, when the squeeze was at its most intense. With shorts largely gone and borrow cheap, the technical tailwind that drove the move has largely exhausted itself. The options market tells a consistent story: the put/call ratio is 0.10, far below the 20-day average of 0.21, meaning call activity dominates overwhelmingly. Bulls pressed the chase through May.
JP Morgan disagrees. Lisa Gill downgraded AGL to Underweight on May 4 — two days ago — from Neutral, setting a $21 price target. At $26.74, that implies roughly 21% downside to the firm's view. The broader analyst consensus is similarly cautious: 12 holds and three underperforms, with the mean price target at $20.73. The Street, in aggregate, is priced where the stock currently trades. The return potential from consensus sits at -22%. That is an unusual backdrop — a stock trading at a premium to what analysts collectively think it is worth, the day after reporting earnings.
The fundamental debate is live. Bulls point to real operational improvement: total revenue grew 44% year-over-year in Q4, Medicare Advantage membership reached 527,000 — up 36% on the year — and medical costs came in below expectations. The EPS surprise factor score ranks in the 88th percentile, and 90-day EPS momentum is at the very top of the universe. Bears counter with persistent visibility problems: the company reported an adjusted EBITDA loss of $84 million in Q4 2024, and guidance for ACO REACH patients pointed to a sequential decline of 13–20%. The core concern is whether management can convert the top-line growth into sustainable margins, or whether utilisation challenges continue to generate negative surprises.
The earnings history adds one reference point. At the March 17 event, the stock fell 0.9% on the day and then dropped 26.6% over the subsequent five days. The May 6 results have just been announced; price reaction data is not yet available. What to watch: whether today's print shifts the analyst consensus materially, and whether the call-heavy options positioning from the past week gets unwound or extended once the market digests the numbers.
See the live data behind this article on ORTEX.
Open AGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
